Table IV.
Correlation between TRIM28 expression and prognostic factors in patients with breast cancer.
| Prognostic factor | Number of cases | HR | 95% CI | P-value |
|---|---|---|---|---|
| Elston grade | ||||
| I | 308 | 1.98 | 1.14–3.41 | 0.0127 |
| II | 724 | 1.13 | 0.86–1.48 | 0.3734 |
| III | 723 | 1.37 | 1.06–1.76 | 0.0142 |
| Lymph node metastasis | ||||
| Yes | 945 | 1.25 | 1-1.57 | 0.0514 |
| No | 1813 | 1.11 | 0.93–1.33 | 0.2542 |
| Endocrine therapy received | ||||
| Yes | 999 | 1.54 | 1.19–1.98 | 0.0008 |
| No | 1401 | 1.16 | 0.96–1.4 | 0.1341 |
| Chemotherapy received | ||||
| Yes | 425 | 2.14 | 1.51–3.02 | 1×10−05 |
| No | 1974 | 1.21 | 1.02–1.43 | 0.0253 |
Results were analyzed using the Kaplan-Meier Plotter database. P-values were obtained through the log-rank test from the website to compare the relapse free survival rates related to TRIM28 expression. The generated P-value does not include correction for multiple hypotheses testing by default. HR, hazard ratio; CI, confidence interval; TRIM28, tripartite motif containing 28.